Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937418 | 0.91 | CAPN1 (0.41) | CAPN1BRD4MGAMKDM4EGLA | |
| SCHEMBL503017 | 0.80 | KDM4E (0.38) | CAPN1BRD4ADRA2CMGAMMAPK1 | |
| SCHEMBL4778463 | 0.77 | HDAC6 (0.35) | CAPN1BRD4ADRA2CMAPK1L3MBTL1 | |
| SCHEMBL25937442 | 0.74 | CAPN1 (0.43) | CAPN1BRD4ADRA2CKMT2AKDM4E | |
| SCHEMBL16026458 | 0.74 | CAPN1 (0.33) | CAPN1MAPTL3MBTL1 | |
| SCHEMBL11999052 | 0.72 | ADRA2C (0.48) | BRD4ADRA2CMGAMMAPK1KMT2A | |
| Dioxane SCHEMBL9486523 | 0.71 | KDM4E (0.36) | BRD4KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL17360666 | 0.70 | CAPN1 (0.41) | CAPN1KDM4E | |
| SCHEMBL26303973 | 0.70 | CAPN1 (0.41) | CAPN1ADRA2CKMT2A | |
| SCHEMBL10501254 | 0.69 | KDM4E (0.35) | KMT2AKDM4EALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | HDHD5, HAO2, ALAD | CAPN1 3978/4885BRD4 4404/4885ADRA2C 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.